Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Convertible Debt (2017 - 2023)

Neurocrine Biosciences' Convertible Debt history spans 7 years, with the latest figure at $169.5 million for Q1 2023.

  • For Q1 2023, Convertible Debt fell 55.12% year-over-year to $169.5 million; the TTM value through Mar 2023 reached $169.5 million, down 55.12%, while the annual FY2021 figure was $335.1 million, 5.41% up from the prior year.
  • Convertible Debt reached $169.5 million in Q1 2023 per NBIX's latest filing, roughly flat from $169.0 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $414.1 million in Q1 2020 to a low of $169.0 million in Q2 2022.
  • Average Convertible Debt over 5 years is $329.8 million, with a median of $332.9 million recorded in 2021.
  • Peak YoY movement for Convertible Debt: increased 17.3% in 2022, then crashed 55.12% in 2023.
  • A 5-year view of Convertible Debt shows it stood at $403.6 million in 2019, then decreased by 21.23% to $317.9 million in 2020, then increased by 5.41% to $335.1 million in 2021, then plummeted by 49.57% to $169.0 million in 2022, then rose by 0.3% to $169.5 million in 2023.
  • Per Business Quant, the three most recent readings for NBIX's Convertible Debt are $169.5 million (Q1 2023), $169.0 million (Q2 2022), and $377.7 million (Q1 2022).